InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript Summary
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript Summary
Net loss widened to $7.9 million, or $0.16 per share, compared to a net loss of $5.2 million, or $0.15 per share, in the same period last year.The following is a summary of the InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript:
以下是 inspiremd 公司（NSPR）2024年第三季度業績會議實錄摘要：
Financial Performance:
財務表現:
InspireMD reported a revenue of $1.81 million in Q3 2024, a growth of over 16% from the previous year, driven by the sales of 3,100 CGuard implants.
The company saw a decrease in gross profit by 5.6% to $414,000, due to increased miscellaneous expenses, which caused the gross margin to decrease from 28.1% to 22.9%.
Net loss widened to $7.9 million, or $0.16 per share, compared to a net loss of $5.2 million, or $0.15 per share, in the same period last year.
InspireMD 在2024年第三季度報告營業收入爲181萬美元，較上一年增長超過16%，這主要是由於銷售了3,100個CGuard植入裝置。
該公司由於其他雜項費用增加，導致毛利潤下降了5.6%，至414,000美元，致使毛利率由28.1%下降至22.9%。
淨損失擴大至790萬美元，每股虧損0.16美元，而去年同期的淨損失爲520萬美元，每股虧損0.15美元。
Business Progress:
業務進展:
In Q3 2024, InspireMD continued to expand with over 3,100 CGuard implants sold.
Initiated CGuardians 2 pivotal study for the CGuard Prime TCAR indicated carotid stent system, and entered a strategic agreement with the Jacobs Institute at SUNY Buffalo for an early feasibility study of CGuard Prime.
Strengthened commercial and operational structures, including transitioning to a new headquarters in Miami, Florida.
2024年第三季度，InspireMD 繼續擴張，銷售了超過3,100個CGuard植入裝置。
啓動了爲CGuard Prime TCAR 指示性頸動脈支架系統進行的CGuardians 2關鍵性研究，並與 SUNY 布法羅雅各布斯研究所達成戰略協議，進行了CGuard Prime的早期可行性研究。
加強商業和運營結構，包括遷入佛羅里達州邁阿密的新總部。
Opportunities:
機會：
Awaiting U.S. FDA approval for CGuard Prime, anticipated in the first half of 2025, which could significantly boost revenue and market share.
Planning for increases in capital following stages of FDA approval, with potential to raise additional funds from institutional investors.
The expansion into the U.S. market, coupled with the introduction of the SwitchGuard neuroprotection system for TCAR procedures, is expected to significantly drive revenue growth.
等待美國FDA批准CGuard Prime，預計在2025年上半年獲得，這可能極大地提升營業收入和市場份額。
在FDA批准的各階段之後計劃增加資本，有可能從機構投資者那裏籌集額外的資金。
進軍美國市場，並推出SwitchGuard神經保護系統用於TCAR手術，預計將顯著推動營業收入增長。
Risks:
風險：
The gross margin has decreased due to increased expenses, showing potential cost management hazards as the company expand further.
由於成本增加，毛利率下降，展示出在公司進一步擴張時潛在的成本管理隱患。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
